This review aims to assess, acknowledge, and compile data from clinical trials regarding the safety and efficacy of BRAF inhibitor-based combinations in BRAF-mutated CRC for clinicians and to give directions for future clinical trials. Here, BRAF is linked to colorectal carcinoma.